{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-202414","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.378310+00:00","generated_at":"2026-05-14T23:52:57.179106+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aura Biosciences names Natalie Holles CEO; CoMpass trial enrollment at 86 patients, nearing completion","bullets":["New CEO Natalie Holles, former CEO of Third Harmonic Bio and Audentes, appointed effective April 30, 2026.","Founder Elisabet de los Pinos steps down as CEO and director; remains as consultant through October 2026.","Phase 3 CoMpass trial for bel-sar in early choroidal melanoma has 86 patients enrolled; >25 additional patients identified for screening.","Company reiterates guidance: enrollment completion by mid-2026, topline data in H2 2027.","ATM prospectus terminated; $6.7M gross proceeds raised from 1.06M shares sold."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-202414","json":"https://secwatch.observer/filing/0001193125-26-202414.json","markdown":"https://secwatch.observer/filing/0001193125-26-202414.md","text":"https://secwatch.observer/filing/0001193125-26-202414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/d117008d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:52:57.179106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c7b534fa9","claim":"Elisabet de los Pinos departed as Chief Executive Officer and President at Aura Biosciences, Inc..","evidence_excerpt":"Dr. Elisabet de los Pinos, the Company’s founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"a8ad2cf0f1","claim":"Elisabet de los Pinos departed as Director at Aura Biosciences, Inc..","evidence_excerpt":"notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ba9f9b382b","claim":"Natalie Holles was appointed as Chief Executive Officer and President at Aura Biosciences, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}